IPN Stock Analysis: Ipsen | PA
Drug Manufacturers - Specialty & Generic | PA, France | Market Cap: 11.592m EUR | 12M Return: 25.3% | FR0010259150 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.7M
Qual. Beats: 0
Rev. Trend: 96.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ipsen S.A. is a France-based biopharmaceutical company headquartered in Paris, founded in 1929. It operates globally across North America, Europe, and other international markets, with a therapeutic focus on three core areas: oncology, rare disease, and neuroscience. Like most large-cap pharmaceutical companies, Ipsen operates an R&D-intensive business model where revenue depends on a mix of established marketed products and a pipeline of candidates advancing through phased clinical trials.
The companys commercial portfolio includes Somatuline (neuroendocrine tumors and acromegaly), Dysport (motor muscular disorders and medical aesthetics), Decapeptyl (prostate cancer, endometriosis, uterine fibroids, central precocious puberty, female infertility, and early-stage breast cancer), Cabometyx (renal cell carcinoma, second-line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors), Onivyde (second-line metastatic pancreatic cancer), and Bylvay (progressive familial intrahepatic cholestasis and Alagille syndrome). Dysports dual use in therapeutic and aesthetic indications is characteristic of biopharmaceutical companies that monetize the same molecule across medical and consumer-facing markets.
Ipsens development pipeline spans early- and late-stage assets, including Iqirvo for second-line primary biliary cholangitis, Sohonos for fibrodysplasia ossificans progressiva (an ultra-rare bone disease), and IPN60340 in Phase I/II trials for acute myeloid leukemia. Late-stage candidates include Tazverik combinations in Phase III for follicular lymphoma and Tovorafenib in Phase III for pediatric low-grade gliomas, while earlier-stage programs (IPN01194, IPN01195, IPN60300, IPN01203, and IPN10200) target solid tumors and aesthetic/therapeutic indications. The companys pipeline activity, particularly across rare and ultra-rare diseases, aligns with industry trends where orphan-drug development offers regulatory exclusivity incentives and premium pricing.
- Somatuline generic erosion pressures core neuroendocrine franchise revenue
- Dysport gains therapeutic and aesthetic share against Botox competition
- Tovorafenib pediatric glioma launch accelerates oncology segment growth
| Net Income: 512.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 4.62 > 1.0 |
| NWC/Revenue: 41.39% < 20% (prev 38.31%; Δ 3.07% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.30b > Net Income 512.6m |
| Net Debt (-901.6m) to EBITDA (1.49b): -0.61 < 3 |
| Current Ratio: 1.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.9m) vs 12m ago -0.61% < -2% |
| Gross Margin: 67.52% > 18% (prev 82.78%; Δ -15.26% > 0.5%) |
| Asset Turnover: 56.63% > 50% (prev 53.33%; Δ 3.30% > 0%) |
| Interest Coverage Ratio: 25.09 > 6 (EBIT TTM 1.04b / Interest Expense TTM 41.3m) |
| A: 0.22 (Total Current Assets 3.41b - Total Current Liabilities 1.74b) / Total Assets 7.46b |
| B: 0.05 (Retained Earnings 403.1m / Total Assets 7.46b) |
| C: 0.15 (EBIT TTM 1.04b / Avg Total Assets 7.15b) |
| D: 1.71 (Book Value of Equity 4.71b / Total Liabilities 2.75b) |
| Altman-Z'' = 4.42 = AA |
| DSRI: 1.04 (Receivables 1.10b/958.0m, Revenue 4.05b/3.64b) |
| GMI: 1.23 (GM 82.78% / 67.52%) |
| AQI: 0.93 (AQ_t 0.45 / AQ_t-1 0.49) |
| SGI: 1.11 (Revenue 4.05b / 3.64b) |
| TATA: -0.11 (NI 512.6m - CFO 1.30b) / TA 7.46b) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at EUR 142.60 with a total of 99,154 shares traded. Over the past week, the price has changed by +1.42%, over one month by -10.37%, over three months by -11.21% and over the past year by +25.32%.
Current recommended Stop Loss: 137.50 (which is 3.6% or 1.3 ATR below the current price).
Ipsen has no consensus analysts rating.
P/E Trailing = 22.7508
P/E Forward = 10.5485
P/S = 2.7013
P/B = 2.5943
P/EG = 0.5086
Revenue TTM = 4.05b EUR
EBIT TTM = 1.04b EUR
EBITDA TTM = 1.49b EUR
Long Term Debt = 625.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 259.7m EUR (from shortTermDebt, last quarter)
Debt = 1.07b EUR (from shortLongTermDebtTotal, last quarter) + Leases 105.5m
Net Debt = -901.6m EUR (calculated: Debt 1.07b - CCE 1.97b)
Enterprise Value = 10.7b EUR (11.6b + Debt 1.07b - CCE 1.97b)
Interest Coverage Ratio = 25.09 (Ebit TTM 1.04b / Interest Expense TTM 41.3m)
EV/FCF = 8.72x (Enterprise Value 10.7b / FCF TTM 1.23b)
FCF Yield = 11.47% (FCF TTM 1.23b / Enterprise Value 10.7b)
FCF Margin = 30.31% (FCF TTM 1.23b / Revenue TTM 4.05b)
Net Margin = 12.67% (Net Income TTM 512.6m / Revenue TTM 4.05b)
Gross Margin = 67.52% ((Revenue TTM 4.05b - Cost of Revenue TTM 1.31b) / Revenue TTM)
Gross Margin QoQ = 74.52% (prev 59.26%)
Tobins Q-Ratio = 1.43 (Enterprise Value 10.7b / Total Assets 7.46b)
Interest Expense / Debt = 3.86% (Interest Expense 41.3m / Debt 1.07b)
Taxrate = 26.99% (189.2m / 700.9m)
NOPAT = 756.4m (EBIT 1.04b * (1 - 26.99%))
Current Ratio = 1.97 (Total Current Assets 3.41b / Total Current Liabilities 1.74b)
Debt / Equity = 0.23 (Debt 1.07b / totalStockholderEquity, last quarter 4.71b)
Debt / EBITDA = -0.61 (Net Debt -901.6m / EBITDA 1.49b)
Debt / FCF = -0.74 (Net Debt -901.6m / FCF TTM 1.23b)
Total Stockholder Equity = 4.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.17% (Net Income 512.6m / Total Assets 7.46b)
RoE = 11.75% (Net Income TTM 512.6m / Total Stockholder Equity 4.36b)
RoCE = 20.76% (EBIT 1.04b / Capital Employed (Equity 4.36b + L.T.Debt 625.6m))
RoIC = 13.08% (NOPAT 756.4m / Invested Capital 5.78b)
WACC = 5.96% (E(11.6b)/V(12.7b) * Re(6.25%) + D(1.07b)/V(12.7b) * Rd(3.86%) * (1-Tc(0.27)))
Discount Rate = 6.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -28.89 | Cagr: -0.04%
[DCF] Terminal Value 77.97% ; FCFF base≈1.06b ; Y1≈1.21b ; Y5≈1.79b
[DCF] Fair Price = 337.0 (EV 26.9b - Net Debt -901.6m = Equity 27.8b / Shares 82.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.78 | Revenue CAGR: 8.67% | SUE: 1.42 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=15.08 | Chg30d=+0.91% | Revisions=-40% | GrowthEPS=+24.7% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=13.92 | Chg30d=+0.18% | Revisions=-40% | GrowthEPS=-7.7% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -57% (up=0, down=4)